Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Hypercalcaemia in malignancy.

Literature DB >> 2503074

Hypercalcaemia in malignancy.

D A Heath¹.

Abstract

Entities: Disease

Mesh：

Substances：

Year: 1989 PMID： 2503074 PMCID： PMC1836684 DOI： 10.1136/bmj.298.6686.1468

Source DB: PubMed Journal: BMJ ISSN： 0959-8138

× No keyword cloud information.

23 in total

1. Stimulation of bone resorption and inhibition of bone formation in vitro by human tumour necrosis factors.

Authors: D R Bertolini; G E Nedwin; T S Bringman; D D Smith; G R Mundy
Journal: Nature Date: 1986 Feb 6-12 Impact factor: 49.962

2. Role of glucocorticoids in management of malignant hypercalcaemia.

Authors: R C Percival; A J Yates; R E Gray; F E Neal; A R Forrest; J A Kanis
Journal: Br Med J (Clin Res Ed) Date: 1984-08-04

3. Etidronate disodium in the management of malignancy-related hypercalcemia.

Authors: C Hasling; P Charles; L Mosekilde
Journal: Am J Med Date: 1987-02-23 Impact factor: 4.965

4. Circulating intact parathyroid hormone measured by a two-site immunochemiluminometric assay.

Authors: R C Brown; J P Aston; I Weeks; J S Woodhead
Journal: J Clin Endocrinol Metab Date: 1987-09 Impact factor: 5.958

5. A parathyroid hormone-related protein implicated in malignant hypercalcemia: cloning and expression.

Authors: L J Suva; G A Winslow; R E Wettenhall; R G Hammonds; J M Moseley; H Diefenbach-Jagger; C P Rodda; B E Kemp; H Rodriguez; E Y Chen
Journal: Science Date: 1987-08-21 Impact factor: 47.728

6. Parathyroid hormone-related protein of malignancy: active synthetic fragments.

Authors: B E Kemp; J M Moseley; C P Rodda; P R Ebeling; R E Wettenhall; D Stapleton; H Diefenbach-Jagger; F Ure; V P Michelangeli; H A Simmons
Journal: Science Date: 1987-12-11 Impact factor: 47.728

7. Similarity of synthetic peptide from human tumor to parathyroid hormone in vivo and in vitro.

Authors: N Horiuchi; M P Caulfield; J E Fisher; M E Goldman; R L McKee; J E Reagan; J J Levy; R F Nutt; S B Rodan; T L Schofield
Journal: Science Date: 1987-12-11 Impact factor: 47.728

8. Comparison of the renal and skeletal actions of calcitonin in the treatment of severe hypercalcaemia of malignancy.

Authors: D J Hosking; D Gilson
Journal: Q J Med Date: 1984

9. Stimulation of bone resorption in vitro by synthetic transforming growth factor-alpha.

Authors: K J Ibbotson; D R Twardzik; S M D'Souza; W R Hargreaves; G J Todaro; G R Mundy
Journal: Science Date: 1985-05-24 Impact factor: 47.728

10. Parathyroid hormone-like bioactivity in a patient with severe osteitis fibrosa cystica due to malignancy: renotropic actions of a tumour extract as assessed by cytochemical bioassay.

Authors: N Loveridge; G N Kent; D A Heath; E L Jones
Journal: Clin Endocrinol (Oxf) Date: 1985-02 Impact factor: 3.478

8 in total

Review 1. Oncology.

Authors: J S Malpas
Journal: Postgrad Med J Date: 1990-02 Impact factor: 2.401

Hypercalcaemia in malignancy.

1. Stimulation of bone resorption and inhibition of bone formation in vitro by human tumour necrosis factors.

2. Role of glucocorticoids in management of malignant hypercalcaemia.

3. Etidronate disodium in the management of malignancy-related hypercalcemia.

4. Circulating intact parathyroid hormone measured by a two-site immunochemiluminometric assay.

5. A parathyroid hormone-related protein implicated in malignant hypercalcemia: cloning and expression.

6. Parathyroid hormone-related protein of malignancy: active synthetic fragments.

7. Similarity of synthetic peptide from human tumor to parathyroid hormone in vivo and in vitro.

8. Comparison of the renal and skeletal actions of calcitonin in the treatment of severe hypercalcaemia of malignancy.

9. Stimulation of bone resorption in vitro by synthetic transforming growth factor-alpha.

10. Parathyroid hormone-like bioactivity in a patient with severe osteitis fibrosa cystica due to malignancy: renotropic actions of a tumour extract as assessed by cytochemical bioassay.

Review 1. Oncology.

2. Somatostatin analogue treatment for malignant hypercalcaemia.

3. Hypercalcaemia in malignancy.

4. Patients with symptomatic primary hyperparathyroidism: an anaesthetic challenge.

5. Management of hyperparathyroid patients with grave hypercalcemia.

6. [Pamidronate in the treatment of tumor-associated hypercalcemia].

7. [Somatostatin in preoperative therapy and postoperative diagnosis of a patient with Verner Morrison syndrome].

8. Administration of bisphosphonate for hypercalcemia associated with oral cancer.